Published in Clin Exp Immunol on February 01, 1998
Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev (2010) 4.48
Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A (2002) 2.19
DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis (2012) 2.16
Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am J Pathol (2002) 1.58
Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis (2002) 1.57
Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest (1999) 1.51
Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J (2006) 1.45
Regulation of DNA methylation in rheumatoid arthritis synoviocytes. J Immunol (2012) 1.16
PUMA-mediated apoptosis in fibroblast-like synoviocytes does not require p53. Arthritis Res Ther (2006) 0.97
A systems approach to rheumatoid arthritis. PLoS One (2012) 0.96
p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritis. Arthritis Res Ther (2004) 0.95
Apoptosis and p53 expression in rat adjuvant arthritis. Arthritis Res (2000) 0.94
p53 in rheumatoid arthritis synovial fibroblasts at sites of invasion. Ann Rheum Dis (2003) 0.93
The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst (2016) 0.90
Regulation of rheumatoid synoviocyte proliferation by endogenous p53 induction. Clin Exp Immunol (2001) 0.86
p53 in rheumatoid arthritis: friend or foe? Arthritis Res (2000) 0.85
TP53 mutations coincide with the ectopic expression of activation-induced cytidine deaminase in the fibroblast-like synoviocytes derived from a fraction of patients with rheumatoid arthritis. Clin Exp Immunol (2010) 0.83
CIP2A expression is associated with synovial hyperplasia and invasive function of fibroblast-like synoviocytes in rheumatoid arthritis. Rheumatol Int (2011) 0.81
Altered expression of TPP1 in fibroblast-like synovial cells might be involved in the pathogenesis of rheumatoid arthritis. Rheumatol Int (2011) 0.81
The p53 status in juvenile chronic arthritis and rheumatoid arthritis. Clin Exp Immunol (2000) 0.80
Over-expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes. Clin Exp Immunol (2004) 0.79
Current perspectives on synovitis. Arthritis Res (1999) 0.77
PUMA decreases the growth of prostate cancer PC-3 cells independent of p53. Oncol Lett (2017) 0.75
Somatic mutations and anti-mutated citrullinated vimentin antibodies in rheumatoid arthritis: comment on the editorial by Levesque et al. Arthritis Rheum (2010) 0.75
DNA Mutations May Not Be the Cause of Cancer. Oncol Ther (2017) 0.75
CIP2A facilitates apoptotic resistance of fibroblast-like synoviocytes in rheumatoid arthritis independent of c-Myc expression. Rheumatol Int (2013) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem (1984) 18.48
Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci U S A (1989) 18.26
Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature (1992) 12.92
Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (1993) 10.72
Clinical implications of the p53 tumor-suppressor gene. N Engl J Med (1993) 7.29
Molecular themes in oncogenesis. Cell (1991) 6.73
Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol (1981) 6.02
Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell (1993) 4.62
Gain of function mutations in p53. Nat Genet (1993) 4.19
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (1991) 3.69
Structural aspects of the p53 protein in relation to gene evolution. Oncogene (1990) 3.64
Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci U S A (1996) 3.38
Tumor suppressor genes. Cell (1991) 3.36
Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum (1995) 1.85
Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol (1996) 1.65
Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res (1992) 1.60
The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J Exp Med (1993) 1.58
Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum (1994) 1.57
Antibodies against p53 in sera from patients with systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum (1997) 1.21
Mutations of the p53 gene in human myeloma cell lines. Oncogene (1992) 1.13
Constitutive expression of c-fos and c-jun, overexpression of ets-2, and reduced expression of metastasis suppressor gene nm23-H1 in rheumatoid arthritis. Ann Rheum Dis (1996) 0.96
P53 and oncogenes expression in psoriasis. Acta Derm Venereol Suppl (Stockh) (1989) 0.87
Oncogene activation in rheumatoid synovium. APMIS (1992) 0.87
Correlation between mutations in p53 gene and protein expression in human lymphomas. Am J Hematol (1997) 0.83
Mutation of the tumor suppressor gene TP53 is not detected in psoriatic skin. J Invest Dermatol (1993) 0.80
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol (2014) 2.84
Solitary myeloma: clinical and prognostic features of a review of 114 cases. Cancer (1981) 2.23
Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum (2001) 2.00
Endocarditis associated with ANCA. Clin Exp Rheumatol (1994) 1.85
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76
Increased percentage of CD3+, CD57+ lymphocytes in patients with rheumatoid arthritis. Correlation with duration of disease. Arthritis Rheum (1993) 1.63
Inflammatory joint disease after immunizations. A report of two cases. Rev Rhum Engl Ed (1997) 1.61
Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. Arthritis Rheum (1990) 1.51
Effect of etanercept on tenosynovitis and nodules in rheumatoid arthritis. Arthritis Rheum (2002) 1.48
Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol (1995) 1.46
Polymorphism of the HLA-DMA and DMB genes in rheumatoid arthritis. Arthritis Rheum (1997) 1.44
Gene transfer to human rheumatoid synovial tissue engrafted in SCID mice. J Rheumatol (1997) 1.43
Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis (2006) 1.42
Ultrasound screening during pregnancy: psychological strain experienced by the investigating staff. Ultrasound Obstet Gynecol (1993) 1.41
Sun exposure and risk of melanoma. Arch Dis Child (2005) 1.40
Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest (1991) 1.38
Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol (1989) 1.33
Antibiotic treatment of venereal disease and Reiter's syndrome in a Greenland population. Arthritis Rheum (1992) 1.31
Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol (1998) 1.29
Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis (2004) 1.29
Radiologic progression in early rheumatoid arthritis treated with methotrexate. J Rheumatol (1999) 1.27
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer (2008) 1.27
Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients. Blood (1984) 1.26
The AIMS2-SF: a short form of the Arthritis Impact Measurement Scales 2. French Quality of Life in Rheumatology Group. Arthritis Rheum (1997) 1.26
Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol (1999) 1.25
Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Ann Rheum Dis (1996) 1.23
Acute osteoporotic vertebral collapse: open study on percutaneous injection of acrylic surgical cement in 20 patients. AJR Am J Roentgenol (1999) 1.23
The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol (2006) 1.21
Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol (1993) 1.17
HL-A antigens in rheumatoid arthritis. Vox Sang (1972) 1.17
Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis (2007) 1.14
Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis (2007) 1.10
Autoantibodies predicting the outcome of rheumatoid arthritis: evaluation in two subsets of patients according to severity of radiographic damage. Ann Rheum Dis (1997) 1.09
Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer (1990) 1.07
Investigation of the HLA component involved in rheumatoid arthritis (RA) by using the marker association-segregation chi-square (MASC) method: rejection of the unifying-shared-epitope hypothesis. Am J Hum Genet (1993) 1.07
Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol (1986) 1.07
Phenotypic and functional characterisation of ovine mesenchymal stem cells: application to a cartilage defect model. Ann Rheum Dis (2007) 1.07
Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol (2008) 1.07
Refractory auto-inflammatory syndrome associated with digenic transmission of low-penetrance tumour necrosis factor receptor-associated periodic syndrome and cryopyrin-associated periodic syndrome mutations. Ann Rheum Dis (2006) 1.07
Rheumatoid nodulosis: report of two new cases and discussion of diagnostic criteria. J Rheumatol (1988) 1.06
WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.06
Anti-heat shock protein 70 kDa and 90 kDa antibodies in serum of patients with rheumatoid arthritis. Ann Rheum Dis (1999) 1.06
A decision tree for genetic diagnosis of hereditary periodic fever in unselected patients. Ann Rheum Dis (2006) 1.04
Objective and subjective sleep disturbances in patients with rheumatoid arthritis. A reappraisal. Arthritis Rheum (1994) 1.04
Seven Achilles tendinitis including 3 complicated by rupture during fluoroquinolone therapy. J Rheumatol (1992) 1.03
Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis. J Gene Med (2007) 1.02
Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy. Ann Rheum Dis (2005) 1.01
Sensitivity of magnetic resonance imaging of the wrist in very early rheumatoid arthritis. Clin Exp Rheumatol (1993) 1.01
Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases. Br J Dermatol (2004) 1.01
Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Br J Rheumatol (1996) 1.01
Modulation of the immune response by the neuro-endocrine axis in rheumatoid arthritis. Clin Exp Rheumatol (1994) 1.00
Clinical significance of antibodies to soluble extractable nuclear antigens (anti-ENA). Ann Rheum Dis (1978) 1.00
Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. Br J Rheumatol (1995) 0.99
Clinical significance of anti-RNP and anti-Sm autoantibodies as determined by immunoblotting and immunoprecipitation in sera from patients with connective tissue diseases. Clin Exp Immunol (1989) 0.99
Stimulation of lymphocytes from rheumatoid arthritis patients by mitogens and IgG. Allerg Immunol (Leipz) (1976) 0.98
Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann Rheum Dis (2007) 0.98
Chordin is underexpressed in ovarian tumors and reduces tumor cell motility. FASEB J (2006) 0.97
Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum (1994) 0.97
Erosive osteoarthritis of the hand: clinical experience with anakinra. Ann Rheum Dis (2009) 0.97
beta 2-Microglobulin and beta 2-microglobulin-binding proteins in inflammatory diseases. Eur J Rheumatol Inflamm (1982) 0.96
Health education intervention strategies: recommendations for future research. Health Educ Q (1995) 0.96
Non-Hodgkin's lymphoma associated with primary Sjögren's syndrome. Eur J Med (1992) 0.94
T cell receptor expression and activation of synovial lymphocyte subsets in patients with rheumatoid arthritis. Phenotyping of multiple synovial sites. Arthritis Rheum (1990) 0.94
Sicca syndrome associated with hepatitis C virus infection. Arthritis Rheum (1996) 0.94
Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo. Immunology (1998) 0.93
Serum beta-2-microglobulin in multiple myeloma: relation to presenting features and clinical status. Eur J Cancer Clin Oncol (1982) 0.92
Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. J Rheumatol (1997) 0.92
Arthritis associated with monoclonal gammapathy: clinical characteristics. Br J Rheumatol (1996) 0.92
[Arthropathy with achilles tendon involvement induced by pefloxacin. Apropos of a case]. Rev Rhum Mal Osteoartic (1991) 0.91
Adeno-associated virus pseudotype 5 vector improves gene transfer in arthritic joints. Hum Gene Ther (2005) 0.91
Growth and immortalization of human myeloma cells in immunodeficient severe combined immunodeficiency mice: a preclinical model. Br J Haematol (2001) 0.91
PLGA microspheres encapsulating siRNA anti-TNFalpha: efficient RNAi-mediated treatment of arthritic joints. Eur J Pharm Biopharm (2012) 0.91
Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer (1986) 0.90
Immunomodulating effect of human placenta-eluted gamma globulins in rheumatoid arthritis. Arthritis Rheum (1982) 0.90
Psoriatic arthritis and HLA antigens. J Rheumatol Suppl (1977) 0.89
Human placenta-eluted gammaglobulins in immunomodulating treatment of rheumatoid arthritis. Am J Med (1985) 0.88
The role of miR-155 in regulatory T cells and rheumatoid arthritis. Clin Immunol (2013) 0.88
Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol (1997) 0.88
[Anemia in rheumatoid polyarthritis. Value of serum ferritin for the estimation of iron stores]. Nouv Presse Med (1982) 0.88
Dysregulation of the hypothalamo-pituitary axis in rheumatoid arthritis. J Rheumatol (1995) 0.87
[Serum beta-2-microglobulin in multiple myeloma. Practical value]. Rev Rhum Mal Osteoartic (1981) 0.87
Interleukin 2 (IL 2) inhibitor in rheumatoid synovial fluid: correlation with prognosis and soluble IL 2 receptor levels. J Clin Immunol (1990) 0.86
Cryocrystalglobulinemia as a cause of systemic vasculopathy and widespread erosive arthropathy. Arthritis Rheum (1996) 0.86
Mononuclear cell retention in rheumatoid synovial tissue engrafted in severe combined immunodeficient (SCID) mice is up-regulated by tumour necrosis factor-alpha (TNF-alpha) and mediated through intercellular adhesion molecule-1 (ICAM-1). Clin Exp Immunol (1996) 0.86
Preliminary evaluation of medical outcomes (including quality of life) and costs in incident RA cases receiving hospital-based multidisciplinary management. Joint Bone Spine (2000) 0.85
[Antibody-dependent cytotoxicity of blood lymphocytes during rheumatoid polyarthritis]. Rev Rhum Mal Osteoartic (1976) 0.85
Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol (1990) 0.85